To carry out a cost-utility analysis of the treatment of relapsing-remitting multiple sclerosis (RRMS) with glatiramer acetate (Copaxone) or interferon beta products (all as a whole, Avonex, Rebif and Betaferon). METHODS: Markov pharmacoeconomic model that compared treatments by simulating the life of a hypothetical cohort of 30-year-old women, from the societal perspective. Transition probabilities, utilities, resource utilization and costs (direct and indirect) were estimated from Spanish sources and bibliography. Simple univariate sensitivity analyses of the base case were performed. RESULTS: In the base case analysis, the average cost per patient (€ in 2001) of life treatment, considering a life expectancy of 53 years, would be €1, 243,906 €1,818,149, €1,763,263, €1,987,153 and €1,704,031 with Copaxone, all the interferons, Avonex, Rebif and Betaferon, respectively. Thus, the savings with Copaxone would range from €460,000 to €737,000 approximately. The quality-adjusted life years (QALY) obtained with Copaxone or the interferons would be 10.977 and 6.917, respectively, with a mean gain of 4.060 QALY/patient with Copaxone. Sensitivity analyses confirmed the robustness of the base case. Interferons would be superior to Copaxone only in the hypothetical and unlikely case that they delay the progression of the illness by 20% more than that presently observed in the clinical trials. CONCLUSIONS: For a typical patient with RRMS, treatment with Copaxone would be more efficient than interferons, which would be dominated by the former (Copaxone would be more effective with lower costs than the latter). 
OBJECTIVES:
Compare different approaches to assessing the association of prophylactic treatment and total migraine-specific costs from administrative data. Evaluate the usefulness of propensity scores. METHODS: Using retrospective, administrative data, two groups of patients were identified: 1) received prophylactic migraine treatment; and 2) potential candidates for prophylaxis. Four methods were applied to compare the log of the total migraine cost between the groups, and to determine the association of prophylaxis with total cost. In the first method, groups were matched based on logit propensity score to adjust for selection bias. In the second, groups were exact case matched on the same variables. In the third method a linear regression model was constructed using all observations in the data. A comparison between the means of total migraine cost, and log of total migraine cost was also evaluated based on a T-test without adjustment for selection bias. Jackknife residual analysis was performed, and statistically significant outliers were eliminated. RESULTS: As typical for cost data, the total migraine cost data was skewed, so the data was log transformed. Results based on different methods showed the same trend; patients treated with migraine prophylaxis had lower total migraine cost. Mean differences (p-value) in total migraine cost and log cost, between the groups, without adjustment for selection bias, were $263 (0.0306) and 0.3192 (<0.0001). Log total migraine cost showed a 29% (<0.0001) (linear regression), 33.5% (<0.0001) (propensity scores method), and 29.6% (<0.0001) (case matched method) reduction in cost for those on prophylaxis. CONCLUSION: The construction of a propensity score model is more complicated and may result in some data loss. The ability of the model to adjust for selection bias depends on how well the propensity score model predicts the treatment variable. The constraints in this retrospective, administrative data limit the usefulness of this approach. 
To examine the direct and indirect costs for adults diagnosed with migraine, as well as the costs associated with comorbid anxiety and/or depression. METHODS: Individuals diagnosed with migraine or receiving a migraine medication between 1999-2000 were identified in a database capturing inpatient, outpatient, and prescription drug services from approximately 45 large employers. The migraine cohort (N = 2519) was matched to a non-migraine cohort (N = 2519) at a 1 : 1 ratio based upon age, gender and metropolitan statistical area. Variables of interest included direct medical costs (inpatient, outpatient, and prescription drug) as well as indirect costs (absenteeism, short-term disability and worker compensation). RESULTS: Adults with migraine had significantly higher inpatient (p = 0.0008), outpatient (p < 0.0001), prescription drug (p < 0.0001), and overall medical costs (p < 0.0001) compared to the non-migraine cohort. In addition, adults with migraine had significantly higher costs associated with absenteeism (p = 0.0010) compared to the healthy cohort. The presence of depres-sion (N = 556) or anxiety (N = 158) in addition to migraine equated to significantly greater outpatient, prescription drug, and total medical costs compared to a healthy comparator group. The differential in total costs (medical plus productivity) between migraine sufferers with comorbid anxiety ($4562, p < 0.0001) or comorbid depression ($6193, p < 0.0001) and the healthy cohort was substantially greater than the differential between migraine sufferers without these comorbidities and their healthy matches ($3638, p < 0.0001). CONCLUSIONS: These results demonstrate and quantify the economic burden in terms of direct and indirect costs to employers of migraine alone and migraine in conjunction with depression or anxiety.
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ECONOMIC COMPARISON OF FIVE TRIPTAN STRATEGIES FOR MIGRAINE HEADACHES USING MONTE CARLO SIMULATION
Bell CF, Hu X, Markson L Merck & Co, Inc, West Point, PA, USA
OBJECTIVE:
To assess, via Monte Carlo simulation, the per-attack drug acquisition cost and effectiveness (proportion of patients pain-free two hours post-dose) of five oral triptan strategies for treatment of acute migraine headaches. METHODS: A Monte Carlo simulation model was used to estimate the average number of patients needed to treat (NNT), relative to placebo, to achieve the efficacy endpoint of one pain-free two hours post-dose (pain-free patient). Efficacy data was obtained from a published meta-analysis of 53 triptan-specific clinical trials. A normal distribution for the proportion of pain-free patients was used and was based on the means and 95% confidence intervals reported in the metaanalysis. Single-dose acquisition costs, based on average wholesale prices (2002US$), were applied to the NNT results, allowing for a per-attack assessment of the cost per pain-free patient. Oral triptans almotriptan, naratriptan, rizatriptan, sumatriptan and zolmitriptan were assessed in the simulation. RESULTS: After 10,000 iterations, the mean NNT (95% CI) to achieve one pain-free patient was 3.31 (2.97-3.71) for rizatriptan, 4.16 (2.83-6.54) for zolmitriptan, 5.06 (3.32-8.53) for almotriptan, 5.14 (4.50-5.92) for sumatriptan and 7.26 (5.52-9.96) for naratriptan. The mean cost (95% CI) per pain-free patient was $55.61 ($36.50-$93.70), $56.60 ($50.81-$63.44), $75.34 ($51.34-$118.61), $88.27 ($77.28-$101.70) and $145.27 ($110.38-$199.27 ) for almotriptan, rizatriptan, zolmitriptan, sumatriptan and naratriptan, respectively. Cost differences between almotriptan and rizatriptan were relatively small, with 38 percent of simulations resulting in cost savings per pain-free patient favoring rizatriptan. CONCLUSIONS: Inasmuch as the results suggested that almotriptan and rizatriptan may be similar on a cost per pain-free patient basis, the NNT results favored rizatriptan, with approximately two fewer patients needed to treat to achieve one pain-free patient. Future economic assessments, including endpoints such as tablet consumption per attack and consistency across multiple attacks, may provide further guidance as to the most cost-effective triptan strategies.
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COST PER SUCCESSFULLY TREATED PATIENT AS MEASURE OF EFFECTIVENESS IN COMPARING ELETRIPTAN TO SUMATRIPTAN
Weis KA Pfizer, Inc, New York, NY, USA OBJECTIVES: Use the outcomes effectiveness measure of a successfully treated patient to compare the costeffectiveness of Eletriptan to Sumatriptan. METHODS: Data for the economic analysis was based on pooled data from three randomized, double blind, placebo-controlled phase III/B clinical trials. Logistic regression with SAS GENMOD was used to fit the model and the CON-TRAST statement was used for the comparisons of interest-the numbers of successfully treated patients. Three measure of success were analyzed: patients with headache response within 2 hours of triptan therapy, sustained to 24 hours; patients with headache response within 1 hour of triptan therapy, sustained to 24 hours, and patients who were pain free within 2 hours of triptan therapy, sustained to 24 hours. The cost-effectiveness measure-cost per successfully treated patient-was calculated as a ratio of the total cost of treating all patients to the number of successfully treated patients for the comparison of Eletriptan 40 mg vs. Sumatriptan 100 mg. The 95% confidence interval for the comparison group for each outcome effectiveness measure was calculated by bootstrapping techniques. RESULTS: The number of successfully treated patients for each of the 3 outcome measures of effectiveness was statistically significantly greater in the Eletriptan 40 mg groups compared to the Sumatriptan 100 mg groups (P-values all =<.002). The 95% confidence interval ranges for each of the Eletriptan costeffectiveness results are smaller and the one for the 2-hour pain free sustained measure does not overlap that of Sumatriptan. CONCLUSIONS: The cost per successfully treated patient is a new composite outcome measure of cost-effectiveness that was consistently lower for all patients treated with Eletriptan 40 mg compared to Sumatriptan 100 mg. Cost-effectiveness using this outcome measure empirically demonstrates the value for the resources spent on migraine therapy.
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COST UTILITY ANALYSIS OF IMMUNOGLOBULINS (IVIG) VERSUS PLASMA EXCHANGE (PE) FOR THE TREATMENT OF GUILLAIN BARRE SYNDROME (GBS)
Jivraj F 1 , Dranitsaris G 2 , Nicolle M
